Several biotechnology and pharmaceutical companies have reported their third-quarter 2024 financial results. TG Therapeutics reported third-quarter U.S. BRIUMVI net revenue of $83.3 million and raised its full-year 2024 U.S. BRIUMVI net revenue target to $300-$305 million. Zoetis announced a 14% increase in total revenue excluding foreign exchange impacts, with U.S. companion animal revenue rising by 18% and U.S. livestock revenue by 5%. Zoetis also raised its 2024 revenue outlook to a 10-11% increase and adjusted EPS to $5.86-$5.92. Zoetis reported revenue of $2.39 billion, beating estimates by $98 million, and EPS of $1.58, beating estimates by $0.13.